We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Advisory Committee Supports Epizyme’s NDA for Epithelioid Sarcoma
Advisory Committee Supports Epizyme’s NDA for Epithelioid Sarcoma
The FDA’s Oncologic Drugs Advisory Committee voted unanimously on Wednesday to recommend approval of Epizyme’s tazemetostat for treatment of metastatic or locally advanced epithelioid sarcoma not eligible for surgery.